Research Feature - Remission Outcomes Following CBT or Supportive Psychotherapy for BDD

Member Since 2018

​“I first became involved in ADAA in 2018, when I attended my first ADAA conference. I initially got involved because the conference was so highly recommended to me by my colleagues. ADAA is a unique organization that joins together professionals with a range of different professional backgrounds, who are all focused on similar clinical domains. Because of that, the scope and content of the conferences feel very relevant. I also appreciate that you can attend the conference and expand your clinical and research skillsets in one place.”

“ADAA offers a community of professionals with complementary skills and expertise both clinically and in research.“

“I was recently promoted to Assistant Professor at Harvard Medical School, in June of 2020.  Additionally, I was awarded a K23 Career Development Award from NIMH in Sept 2019, to fund my research and training focused on smartphone-based detection of high-risk negative emotion states and prediction of related adverse outcomes (i.e., suicidal ideation, substance use) in participants with body dysmorphic disorder. I was selected as runner-up for the 2021 ADAA Donald F. Klein Early Career Investigator Award and I received a 2019 Rising Star Award from the Association for Psychological Science (APS).”

Hilary Weingarden, PhD is an Assistant Professor at Harvard Medical School (HMS) and a staff psychologist in the Center for OCD and Related Disorders (CORD) at Massachusetts General Hospital (MGH). Dr. Weingarden received her bachelor's degree from Tufts University and her PhD in clinical psychology from George Mason University. She completed her clinical internship and postdoctoral training at MGH/HMS and is a licensed psychologist in the state of Massachusetts. Dr. Weingarden's research is focused on cognitive and emotional risk factors for adverse outcomes such as suicide risk in OCD and body dysmorphic disorder (BDD). Her research also focuses on applying technology to enhance assessment of and interventions for OCD and related disorders. Her work is currently supported by a Career Development Award (K23) from the National Institute of Mental Health. In addition to NIMH, Dr. Weingarden's work has been funded as Principal Investigator or co-Investigator by Harvard Medical School and industry collaborations, and she was a 2019 recipient of the Association for Psychological Science's (APS) Rising Star Award. In addition to her work at MGH, Dr. Weingarden has a private practice where she provides evidence-based psychological treatments for adults with OCD and related disorders.